Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Clinical experience with the recently developed progestogens.

S O Skouby1, K R Petersen

  • 1Department of Obstetrics and Gynecology Rigshospitalet, University of Copenhagen, Denmark.

International Journal of Fertility
|January 1, 1991
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Progesterone and 17-hydroxy-progesterone concentrations in follicular fluid and serum reflect their production in granulosa and theca cells.

Reproductive biomedicine online·2024
Same author

Reply: Impact of letrozole-associated controlled ovarian hyperstimulation on ART outcomes and endocrinological parameters.

Human reproduction (Oxford, England)·2022
Same author

A distinctive epigenetic ageing profile in human granulosa cells.

Human reproduction (Oxford, England)·2020
Same author

Response to ovulation trigger is correlated to late follicular phase progesterone levels: A hypothesis explaining reduced reproductive outcomes caused by increased late follicular progesterone rise.

Human reproduction (Oxford, England)·2019
Same author

Semen quality associated with subsequent hospitalizations - Can the effect be explained by socio-economic status and lifestyle factors?

Andrology·2018
Same author

Polycystic ovary syndrome and low-grade inflammation with special reference to YKL-40.

Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology·2014

Third-generation oral contraceptives (OCs) offer effective contraception with potentially improved cycle control and fewer side effects than older formulations. These newer progestogens show a neutral or beneficial impact on cardiovascular health and lipid metabolism.

Area of Science:

  • Reproductive endocrinology
  • Pharmacology of oral contraceptives

Background:

  • Third-generation oral contraceptives (OCs) utilize newer progestogens like gonanes (norgestimate, desogestrel, gestodene) introduced in the 1980s.
  • These differ structurally from older progestogens (norethindrone, norgestrel/levonorgestrel) but are potent ovulation inhibitors with high endometrial receptor selectivity.

Purpose of the Study:

  • To review the efficacy, side effect profile, and metabolic/cardiovascular effects of third-generation combined oral contraceptives.
  • To compare these newer agents with traditional OCs based on available data.

Main Methods:

  • Review of existing literature and clinical experience with third-generation combined oral contraceptives.
  • Comparative analysis of efficacy, cycle control, side effects, and metabolic/cardiovascular parameters against older OC generations.
Keywords:
BiologyBleedingCarbohydrate Metabolic EffectsComparative StudiesContraceptionContraceptive Agents, Female--beneficial effectsContraceptive Agents, Female--pharmacodynamicsContraceptive Agents, Progestin--pharmacodynamicsContraceptive Agents--beneficial effectsContraceptive Agents--pharmacodynamicsContraceptive EffectivenessContraceptive Methods--side effectsContraceptive Mode Of ActionContraceptive UsageDenmarkDeveloped CountriesDiseasesEmbolismEuropeFamily PlanningGlucose Metabolism EffectsLipid Metabolic EffectsLipidsLiterature ReviewMenstrual CycleMenstruationMetabolic EffectsMethod AcceptabilityNorthern EuropeOral Contraceptives, Combined--side effectsOral Contraceptives--side effectsOvulation SuppressionPearl's FormulaPhysiologyProgestins, Low-dose--beneficial effectsReproductionResearch MethodologyScandinaviaSigns And SymptomsStudiesSwedenThromboembolismThrombosisUnited KingdomUse-effectivenessVascular Diseases

Related Experiment Videos

Main Results:

  • Third-generation OCs demonstrate comparable efficacy to traditional OCs, with potentially superior cycle control.
  • Incidence of minor side effects like nausea, weight gain, and breast tenderness appears favorable compared to earlier OCs.
  • These newer progestogens exhibit a neutral or beneficial effect on lipid/lipoprotein metabolism, with no apparent adverse cardiovascular impact.

Conclusions:

  • Third-generation combined OCs are efficacious and well-tolerated alternatives to traditional formulations.
  • They offer potential advantages in cycle control, side effect profile, and metabolic/cardiovascular safety.
  • These agents provide contraceptive benefits alongside a range of noncontraceptive health advantages.